Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Care Coordination, Family-Centered Care, and Functional Ability in Children with Special Health Care Needs in the United States
Marti-Morales, Madeline, Rohrer, James E.

Population Health Management | August 15, 2014 | Volume: 17 | Issue: 4 | Pages: 233-238

10.1089/pop.2013.0092 | PMID 25127206 Get It

The purpose of this study was to determine if there was an association between care coordination, family-centered care, and functional ability among children with special health care needs (CSHCN). Analysis of data from the 2005–2006 National Survey of CSHCN revealed that the percentages of CSHCN receiving care coordination and family-centered care were 59.3 and 66.3, respectively. Children who did not receive care coordination had a 53% higher adjusted odds (odds ratio=1.53, 95% confidence interval 1.21–1.94, P <0.001) for a limitation in functional ability compared to CSHCN who received care coordination. Family-centered care was not associated with a limitation in functional ability in CSHCN ( P =0.61). CSHCN are underserved with regard to care coordination and this appears to be associated with impaired functional ability. Longitudinal studies are needed to confirm causality. ( Population Health Management 2014;17:233–238)
Biomarker and More: Can Translocator Protein 18 kDa Predict Recovery from Brain Injury and Myocarditis?
Fairweather, DeLisa , Guilarte, Tomás R. , Cooper, Leslie T. , Fairweather, DeLisa , Cooper, Leslie T

Biomarkers in Medicine | August 15, 2014 | Volume: 8 | Issue: 5 | Pages: 605-607

10.2217/bmm.14.46 | PMID 25123025 Get It

Delphi definition of the EADC‐ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance
Boccardi, Marina , Bocchetta, Martina , Apostolova, Liana G. , Barnes, Josephine , Bartzokis, George, Corbetta, Gabriele , DeCarli, Charles , deToledo‐Morrell, Leyla, Ganzola, Rossana , Gerritsen, Lotte , Henneman, Wouter J.P., Malykhin, Nikolai , Pasqualetti, Patrizio , Pruessner, Jens C. , Redolfi, Alberto , Robitaille, Nicolas , Tolomeo, Daniele , Watson, Craig, Duvernoy, Henri M., Duchesne, Simon , Jack, Clifford R. , Frisoni, Giovanni B. , Segmentation, EADC‐ADNI Working Group on the Harmonized Protocol for Manual Hippocampal, Boccardi, Marina , Frisoni, Giovanni B. , DeCarli, Charles , Firbank, Michael John , Killiany, Ronald , Soininen, Hilkka S. , Wang, Lei , Wolf, Henrike , Segmentation, EADC‐ADNI Working Group on the Harmonized Protocol for Manual Hippocampal, Jack, Clifford R , Bocchetta, Martina

Alzheimer's & Dementia | August 15, 2014 | Volume: 11 | Issue: 2 | Pages: 126-138

10.1016/j.jalz.2014.02.009 | PMID 25130658 Get It

Abstract Background This study aimed to have international experts converge on a harmonized definition of whole hippocampus boundaries and segmentation procedures, to define standard operating procedures for magnetic resonance (MR)‐based manual hippocampal segmentation. Methods The panel received a questionnaire regarding whole hippocampus boundaries and segmentation procedures. Quantitative information was supplied to allow evidence‐based answers. A recursive and anonymous Delphi procedure was used to achieve convergence. Significance of agreement among panelists was assessed by exact probability on Fisher's and binomial tests. Results Agreement was significant on the inclusion of alveus/fimbria ( P = .021), whole hippocampal tail ( P = .013), medial border of the body according to visible morphology ( P = .0006), and on this combined set of features ( P = .001). This definition captures 100% of hippocampal tissue, 100% of Alzheimer’s disease‐related atrophy, and demonstrated good reliability on preliminary intrarater (0.98) and inter‐rater (0.94) estimates. Discussion Consensus was achieved among international experts with respect to hippocampal segmentation using MR resulting in a harmonized segmentation protocol.
Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case‐control study
Fiandaca, Massimo S. , Kapogiannis, Dimitrios , Mapstone, Mark , Boxer, Adam L. , Eitan, Erez , Petersen, Ronald C. , Federoff, Howard J. , Goetzl, Edward J. , Eitan, Erez , Schwartz, Janice B. , Abner, Erin L. , Miller, Bruce L.

Alzheimer's & Dementia | August 15, 2014 | Volume: 11 | Issue: 6 | Pages: 600

10.1016/j.jalz.2014.06.008 | PMID 25130657 Get It

Abstract Background Proteins pathogenic in Alzheimer's disease (AD) were extracted from neurally derived blood exosomes and quantified to develop biomarkers for the staging of sporadic AD. Methods Blood exosomes obtained at one time‐point from patients with AD (n = 57) or frontotemporal dementia (FTD) (n = 16), and at two time‐points from others (n = 24) when cognitively normal and 1 to 10 years later when diagnosed with AD were enriched for neural sources by immunoabsorption. AD‐pathogenic exosomal proteins were extracted and quantified by enzyme‐linked immunosorbent assays. Results Mean exosomal levels of total tau, P‐T181‐tau, P‐S396‐tau, and amyloid β 1–42 (Aβ1–42) for AD and levels of P‐T181‐tau and Aβ1–42 for FTD were significantly higher than for case‐controls. Step‐wise discriminant modeling incorporated P‐T181‐tau, P‐S396‐tau, and Aβ1–42 in AD, but only P‐T181‐tau in FTD. Classification of 96.4% of AD patients and 87.5% of FTD patients was correct. In 24 AD patients, exosomal levels of P‐S396‐tau, P‐T181‐tau, and Aβ1–42 were significantly higher than for controls both 1 to 10 years before and when diagnosed with AD. Conclusions Levels of P‐S396‐tau, P‐T181‐tau, and Aβ1–42 in extracts of neurally derived blood exosomes predict the development of AD up to 10 years before clinical onset.
Inhibition of Endoglin–GIPC Interaction Inhibits Pancreatic Cancer Cell Growth
Pal, Krishnendu , Pletnev, Alexandre A., Dutta, Shamit K., Wang, Enfeng , Zhao, Ruizhi , Baral, Aradhita, Yadav, Vinod Kumar , Aggarwal, Suruchi , Krishnaswamy, Soundararajan, Alkharfy, Khalid M. , Chowdhury, Shantanu , Spaller, Mark R., Mukhopadhyay, Debabrata , Pal, Krishnendu

Molecular Cancer Therapeutics | August 15, 2014 | Volume: 13 | Issue: 10 | Pages: 2264-2275

10.1158/1535-7163.mct-14-0291 | PMID 25125675 Get It

Abstract Endoglin, a 180-kDa disulfide-linked homodimeric transmembrane receptor protein mostly expressed in tumor-associated endothelial cells, is an endogenous binding partner of GAIP-interacting protein, C terminus (GIPC). Endoglin functions as a coreceptor of TβRII that binds TGFβ and is important for vascular development, and consequently has become a compelling target for antiangiogenic therapies. A few recent studies in gastrointestinal stromal tumor (GIST), breast cancer, and ovarian cancer, however, suggest that endoglin is upregulated in tumor cells and is associated with poor prognosis. These findings indicate a broader role of endoglin in tumor biology, beyond angiogenic effects. The goal of our current study is to evaluate the effects of targeting endoglin in pancreatic cancer both in vitro and in vivo. We analyzed the antiproliferative effect of both RNAi-based and peptide ligand-based inhibition of endoglin in pancreatic cancer cell lines, the latter yielding a GIPC PDZ domain-targeting lipopeptide with notable antiproliferative activity. We further demonstrated that endoglin inhibition induced a differentiation phenotype in the pancreatic cancer cells and sensitized them against conventional chemotherapeutic drug gemcitabine. Most importantly, we have demonstrated the antitumor effect of both RNAi-based and competitive inhibitor–based blocking of endoglin in pancreatic cancer xenograft models in vivo. To our knowledge, this is the first report exploring the effect of targeting endoglin in pancreatic cancer cells. Mol Cancer Ther; 13(10); 2264–75. ©2014 AACR.
Reducing caregiver stress with internet-based interventions: a systematic review of open-label and randomized controlled trials
Hu, Chunling , Kung, Simon , Rummans, Teresa A. , Clark, Matthew M. , Lapid, Maria I. , Hu, Chunling

Journal of the American Medical Informatics Association | August 15, 2014 | Volume: 22 | Issue: e1 | Pages: e194-e209

10.1136/amiajnl-2014-002817 | PMID 25125686 Get It

AbstractObjective The high level of stress associated with caring for others with medical conditions has been recognized for some time. Reducing caregiver stress can improve caregiver quality of life as well as improve the care they provide to loved ones. This systematic review assesses the effectiveness of internet-based interventions to decrease caregiver stress.Materials and methods A comprehensive literature search of Ovid MEDLINE (1946–2013), Embase (1988–2013), PsycINFO (1987–2013), and CINAHL was conducted using terms related to caregiver and internet-based interventions. Internet-based interventions involving informal caregivers in an open-label or randomized controlled trial setting were included. A pair of raters independently reviewed all published abstracts. Data regarding participants, interventions, and outcomes were extracted and, for randomized trials, methodology quality was also reviewed.Results Eight open-label trials met the review criteria: three showed positive benefit in reducing caregiver stress, four were partially positive (some outcomes positive, others negative), and one was a negative study. Sixteen randomized trials met the review criteria: six showed positive benefit, five were partially positive, and five were negative. There were no clear patterns as to the variables (such as study duration and complexity of intervention) associated with better outcomes, although earlier studies typically had more negative outcomes.Discussion Internet-based interventions were mostly effective in reducing aspects of caregiver stress and improving their well-being. Further studies to assess outcomes for caregivers and their recipients’ health, different technology delivery methods, and the cost of such interventions are needed.
Benefit of statin pretreatment in prevention of contrast-induced nephropathy in different adult patient population: systematic review and meta-analysis
Singh, Nirmal, Lee, Justin Z. , Huang, Jennifer J. , Howe, Carol , Pandit, Anil , Suryanarayana, Prakash, Lee, Kwan , Low, See‐Wei , Lee, Kwan S

Open Heart | August 15, 2014 | Volume: 1 | Issue: 1 | Pages: e000127

10.1136/openhrt-2014-000127 | PMID 25332824 Get It

Objective Previous studies have suggested that statin pretreatment prevents contrast-induced nephropathy (CIN). However, single randomised trials are limited in their number of patients. This meta-analysis aims to assess the role of statin use in CIN prevention, as well as to determine patient subgroups that will benefit from statin pre-treatment. Methodology We searched PubMed, EMBASE, Web of science and the Cochrane Central Register of Controlled Trials databases for randomised controlled trials (RCT) comparing statin pretreatment versus placebo for preventing CIN. Our main outcome was the risk of CIN within 1–5 days after contrast administration. Results Data analysed from nine randomised studies with a total of 5143 patients, where 2559 received statins and 2584 received placebo, showed that statin pretreatment was associated with significant reduction in risk of CIN (MH-RR=0.47, 95% CI 0.34 to 0.64, Z=4.49, p<0.00001). This beneficial effect of statin was also seen in patients with baseline renal impairment (MH-RR=0.46, 95% CI 0.29 to 0.72, p=0.0008) and also those who were cotreated with NAC (MH-RR=0.46, 95% CI 0.25 to 0.83, p=0.01). Conclusions Statin pretreatment leads to significant reduction in CIN, and should be strongly considered in all patients who are planned for diagnostic and interventional procedures involving contrast-media administration.
Abstract LB-234: A comparative genomic approach for identifying synthetic lethal interactions in human cancer.
Deshpande, Raamesh, Klebig, Mitchell, Sutor, Shari L., Piotrowski, Jeff S. , Boone, Charles , Wigle, Dennis A. , Myers, Chad L. , Asiedu, Michael K. , Kuzmin, Elena , Shin, Seung Ho , Costanzo, Michael

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: LB-234-LB-234

10.1158/1538-7445.am2013-lb-234 Get It

Abstract Synthetic lethal interactions enable a novel approach for discovering specific genetic vulnerabilities in cancer cells that can be exploited for the development of therapeutics. This concept has recently been exploited in the development of PARP inhibitors as novel chemotherapeutics for breast cancer. While PARP is not essential in normal cells, BRCA mutant cells are dependent on it for their survival. This led to the successful treatment of BRCA mutant tumors of the breast, ovary, and prostate with the oral PARP inhibitor, olaparib. Therapeutic strategies based on such synthetic-lethal (SL) interactions can enable drug targeting of cancer-specific alterations for otherwise undruggable tumor suppressors. Large-scale analyses of genetic interaction networks in model organisms like yeast suggest that disease-specific networks should not only give rise to destructive phenotypes (e.g. uncontrolled cell growth), but will also present unique vulnerabilities that can be exploited for novel therapies. Despite successes in model organisms such as yeast, discovering synthetic lethal interactions on a large scale in human cells remains a significant challenge. We have used a combination of computational and experimental approach whereby yeast interactions between human orthologs are filtered by cancer association and prioritized by genomic features, and candidates from the prioritized list are then validated in human cell lines using an RNA interference approach. As a proof of principle, we utilized this approach to discover two previously unknown synthetic lethal/sick interactions, one between SMARCB1 (yeast SNF5) and PSMA4 (yeast PRE9), and another between ASPSCR1 (yeast UBX4) and PSMC2 (yeast RPT1) based on shRNA double knock-down in normal human fibroblast cells. These interactions suggest potentially new therapeutic targets for SMARCB1 and ASPSCR1 mutated cancers, and more broadly, illustrate the potential of this cross-species approach. Citation Format: Michael K. Asiedu, Raamesh Deshpande, Mitchell Klebig, Shari Sutor, Elena Kuzmin, Jeff Piotrowski, Seung Ho Shin, Michael Costanzo, Charles Boone, Dennis A. Wigle, Chad L Myers. A comparative genomic approach for identifying synthetic lethal interactions in human cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-234. doi:10.1158/1538-7445.AM2013-LB-234
Abstract 94: Identifying biomarkers of estrogen response in models of serous ovarian cancer.
Sikora, Matthew J. , Oesterreich, Steffi , Andersen, Courtney L. , Haluska, Paul

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: 94-94

10.1158/1538-7445.am2013-94 Get It

Abstract Ovarian cancer is the fifth leading cause of cancer death among women in the United States. Despite advances in treatment for other cancers, ovarian cancer patient prognosis has not improved significantly since the advent of platinum-based chemotherapy. It is a highly heterogeneous disease with at least four distinct histological subtypes: serous, mucinous, endometrioid, and clear cell. However, no subtype- or biomarker-specific therapies are approved for ovarian cancer. Identifying targeted therapies is crucial to improving clinical outcomes. Specific therapies will likely vary based on tumor histology and biomarkers. Expression of estrogen receptor alpha (ER) is a well established biomarker of response to endocrine therapies in breast cancer. Despite the success of anti-estrogen therapies in treating breast cancer, little attention has been given to their potential in ovarian cancer. However, epidemiologic studies show that approximately 70% of epithelial ovarian tumors express ER, particularly serous and endometrioid subtypes, and that estrogen plays a role in ovarian cancer etiology. Further, clinical data suggest that a subset of ovarian cancer patients can be successfully treated with endocrine therapy. We hypothesize that some ovarian tumors require estrogen for growth and that predictive biomarkers will identify patients who will benefit from endocrine therapy. Using cell line models, we examined the response of ovarian cancer cells to estrogen (E2) and anti-estrogens with regard to gene expression and cell proliferation. E2 induces expression of canonical ER target genes (e.g. GREB1) in these cells, suggesting that they are estrogen-responsive. We observe that 4-hydroxytamoxifen and fulvestrant inhibit growth of ovarian cancer cells including the chemo-resistant line PEO4. Gene expression microarray studies identified additional E2-regulated genes in ovarian cancer cells that may be utilized as biomarkers of ER activity. We are expanding our studies to in vivo models (human primary tumor xenografts) to evaluate the role of E2 in driving tumor progression and determine the efficacy of anti-estrogens in treating serous ovarian cancer. There is a critical need for targeted therapies in ovarian cancer. Our studies will determine if endocrine responsiveness correlates with gene expression of specific biomarkers, which may lead to the identification of predictive clinical markers of response to endocrine therapy. Citation Format: Courtney L. Andersen, Matthew J. Sikora, Paul Haluska, Steffi Oesterreich. Identifying biomarkers of estrogen response in models of serous ovarian cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 94. doi:10.1158/1538-7445.AM2013-94
Abstract 5358: BRCA1 is a negative modulator of the PRC2 complex.
Zeng, Xianzhou , Chen, Shuai , Wang, Lan , Huang, Haojie

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: 5358-5358

10.1158/1538-7445.am2013-5358 Get It

Abstract The Polycomb repressive complex 2 (PRC2) is important for maintenance of stem cell pluripotency and suppression of cell differentiation by promoting histone H3 lysine 27 trimethylation (H3K27me3) and transcriptional repression of differentiation regulatory genes. Here we show that the tumor suppressor protein BRCA1 interacts with EZH2 and other components of PRC2 in mouse embryonic stem (ES) and human breast cancer cells. The BRCA1-binding region in EZH2 overlaps with the non-coding RNA (ncRNA)-binding domain, and BRCA1 expression inhibits the binding of EZH2 to the HOTAIR ncRNA. Decreased expression of BRCA1 causes EZH2 re-targeting genome wide and elevates H3K27me3 levels at PRC2 target loci in both mouse ES and human breast cancer cells. BRCA1 deficiency blocks ES cell differentiation and enhances breast cancer migration and invasion in an EZH2-dependent manner. These results reveal that BRCA1 is a key negative modulator of PRC2 and that loss of BRCA1 inhibits ES cell differentiation and enhances cancer aggressive phenotypes via augmented PRC2 function. Citation Format: Xianzhou Zeng, Shuai Chen, Lan Wang, Haojie Huang. BRCA1 is a negative modulator of the PRC2 complex. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5358. doi:10.1158/1538-7445.AM2013-5358